Skip to content
Screener

Boston Scientific BSX Cardiovascular — Depreciation

Other segment segments

MedSurg
$29M+7.4%

Similar metrics at other companies

Medtronic logo
MDTCardiovascular — Depreciation
$67M+15.5%
Medtronic logo
MDTNeuroscience — Depreciation
$85M+18.1%
Danaher logo
DHRBiotechnology — Depreciation
$40M+5.3%
Danaher logo
DHRDiagnostics — Depreciation
$107M+7.0%
Comfort Systems USA logo
FIXMechanical — Depreciation
$16.41M+35.7%
GLW
GLWAutomotive — Depreciation
$39M-4.9%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$69.19B-54.6%
P/E18.9×-42.3×
P/S3.3×-5.0×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
Depreciation expense (in millions)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
MedSurg$29$27
Cardiovascular8978
Consolidated depreciation expense$118$106

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's cardiovascular — depreciation?
Boston Scientific (BSX) reported cardiovascular — depreciation of $89M in Q1 2026.
How has Boston Scientific's cardiovascular — depreciation changed year-over-year?
Boston Scientific's cardiovascular — depreciation increased by 14.1% year-over-year, from $78M to $89M.
What is the long-term trend for Boston Scientific's cardiovascular — depreciation?
Over 4 years (2021 to 2025), Boston Scientific's cardiovascular — depreciation has grown at a 8.0% compound annual growth rate (CAGR), from $261M to $355M.
What does cardiovascular — depreciation mean?
This metric tracks the systematic allocation of the cost of tangible assets used specifically within the cardiovascular segment over their useful lives. It reflects the capital intensity required to maintain the manufacturing and operational infrastructure for cardiovascular devices.

Ask your AI about Boston Scientific's cardiovascular — depreciation.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude